Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: A3 adenosine receptor agonists - Can-Fite BioPharma

Drug Profile

Research programme: A3 adenosine receptor agonists - Can-Fite BioPharma

Alternative Names: A3 adenosine receptor allosteric modulators - Can-Fite BioPharma; CF 402; CF-402 - Can-Fite BioPharma; CF-502

Latest Information Update: 18 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Can-Fite BioPharma; Leiden University; National Institutes of Health (USA)
  • Developer Can-Fite BioPharma
  • Class Amides; Anti-inflammatories; Cyclohexanes; Quinolines; Small molecules
  • Mechanism of Action Adenosine A3 receptor agonists; Nitric oxide stimulants; Vascular endothelial growth factors stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Sexual function disorders
  • No development reported Autoimmune disorders; Inflammation

Most Recent Events

  • 18 Apr 2019 9265044: No updates
  • 18 Jul 2018 Can-Fite BioPharma has patent protection for A3 adenosine receptor (A3AR) agonists in Australia and China
  • 17 Nov 2017 Preclinical development is ongoing for Erectile dysfunction and Sexual-function-disorders in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top